Recent News

• 06.13.2025 - Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
• 06.06.2025 - Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
• 06.04.2025 - Jefferies Global Healthcare Conference
• 06.03.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.28.2025 - Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference
• 05.23.2025 - Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
• 05.22.2025 - Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
• 05.13.2025 - Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Recent Filings

• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 8-K Current report
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors